MedTrace Logo

Efficacy of Diacerein on Ocular Surface Disease in Degenerative Arthritis Patients

NCT04351100 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 34

Last updated 2021-08-10

No results posted yet for this study

Summary

Dry eyes is multi-factorial disease which inflammation play etiological role. Diacerein is drug which has anti-inflammatory effect by antagonist Interleukin-1, decrease Interleukin-1 receptor, increase Interleukin-1 Receptor antagonist. This observational study enrolled participants who going to take diacerein for osteoarthritis, measure corneal staining score, Ocular surface disease index score, Tear Osmolarity, Tear break up time, Schirmer 1 test, Interleukin-1 Receptor antagonist, Interleukin-1 alpha, Interleukin-1 beta level in tear at the time of enrollment and after 2 months.

Conditions

Interventions

DRUG

Diacerein

Diacerein prescribing by orthopedist. Dry eye sign and symptom was asses before start diacerein and after 2 months.

Sponsors & Collaborators

  • Chulalongkorn University

    lead OTHER

Principal Investigators

  • Ngamjit Kasetsuwan · Department of Ophthalmology, Chulalongkorn University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2020-07-31
Completion
2020-07-31

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04351100 on ClinicalTrials.gov